Melatonin as a potential therapeutic agent in psychiatric illness

Human Psychopharmacology

Volumn 24, Issue 5, 2009, Pages 391-400

  Maldonado, Maria D ^a   Reiter, Russel J ^b   Pérez San Gregorio, Maria A ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Immune function; Major psychiatric disorders; Melatonin; Neuroinflammation

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; DIAZEPAM; HALOPERIDOL; IBUPROFEN; LITHIUM SALT; MELATONIN; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PERPHENAZINE; PHENOBARBITAL; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE; ZUCLOPENTHIXOL; ANTIOXIDANT;

AGRANULOCYTOSIS; AMNESIA; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; ANXIETY; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTION; EOSINOPHILIA; EPILEPSY; FOOD; FOOD DRUG INTERACTION; HEART ARRHYTHMIA; HUMAN; HYPERTENSIVE CRISIS; INFLAMMATION; INSOMNIA; MENTAL DISEASE; METABOLIC SYNDROME X; MIGRAINE; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PERSONALITY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLEEP WAKING CYCLE; TARDIVE DYSKINESIA; TRANQUILIZING ACTIVITY; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ANIMAL; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; HUMANS; MELATONIN; MENTAL DISORDERS;

EID: 70149114138     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1032     Document Type: Review

References (133)

1. Acuña-Castroviejo D. 2007. A new guest playing with bone and fat. Am J Physiol Regul Integr Comp Physiol 292: R2206-R2207.
2. Agez L, Laurent V, Guerrero HY, et al. 2009. Endogenous melatonin provides an effective circadian message to both the suprachiasmatic nuclei and the pars tuberalis of the rat. J Pineal Res 46: 95-105.
3. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). American Psychiatric Press: Washington, DC.
4. Ancoli-Israel S, Martin JL. 2006. Insomnia and daytime napping in older adults. J Clin Sleep Med 2: 333-342.
5. Baskak SC, Ozsan H, Baskak B, et al. 2008. Peripheral blood T-lymphocyte and T-lymphocyte subset ratios before and after treatment in schizophrenia patients not taking antipsychotic medication. Turk Psikiyatri Derg 19: 5-12.
6. Battaglino R, Vokes M, Schulze S, et al. 2007. Fluoxetine treatment increases trabecular bone formation in mice (fluoxetine affects bone mass). J Cell Biochem 100: 1387-1394.
7. Benson KL. 2006. Sleep in schizophrenia: impairments, correlates, and treatment. Psychiatr Clin North Am 29: 1033-1045.
8. Bersani G, Garavini A. 2000. Melatonin add-on in manic patients with treatment resistant insomnia. Prog Neuropsychopharmacol Biol Psychiatry 24: 185-191.
9. Borda M, Pérez-San-Gregorio MA, Blanco A. 2000. Conduct modification techniques manual in behavioral medicine. Publications of the University of Seville 63-117.
10. Bruce LR. 2007. Worried sick: antidepressants, stress and inflammation. J Clin Psychiatry 68: 10.
11. Cardinali DP, Ladizesky MG, Boggio V, et al. 2003. Melatonin effects on bone: experimental facts and clinical perspective. J Pineal Res 34: 81-87.
12. Carrillo-Vico A, Calvo JR, Abreu P, et al. 2004. Evidence of melatonin síntesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 18: 537-539.
13. Carrillo-Vico A, Lardone PJ, Naji L, et al. 2005a. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and antiapoptotic effects. J Pineal Res 39: 400-408.
14. Carrillo-Vico A, Lardone PJ, Fernández-Santos JM, et al. 2005b. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin 2/interleukin 2 receptor system. J Clin Endocrinol Metab 90: 992-1000.
15. Casademont J, Garrabou G, Miró O, et al. 2007. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mono-nuclear cells analysis in psychotic patients. J Clin Psychopharmacol 27: 284-288.
16. Castanon N, Leonard BE, Neveu PJ, Yirmiya R. 2002. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 16: 569-574.
17. Chakroun N, Doron J, Swendsen J. 2004. Substance use, affective problems and personality traits: test of two associations models. Encephale 30: 564-569.
18. Cheung RT, Tipoe GL, Tam S, et al. 2006. Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res 41: 337-343.
19. Darko DF, Rose J, Gillin JC, et al. 1988. Neutrophilia and lymphopenia in major mood disorders. Psychiatry Res 25: 243-251.
20. Diem SJ, Blackwell TL, Stone KL, et al. 2007. Use of antidepressnts and rates of hip bone loss in older women. Arch Intern Med 167: 1240-1245.
21. Dowling GA, Burr RL, Van Someren EJ, et al. 2008. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc 56: 239-246.
22. Ducovich ML, Markowska M. 2005. Functional MT1 and MT2 melatoninreceptors in mammals. Endocrine 27: 101-110.
23. Fagiolini A, Frank E, Scott JA, et al. 2005. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 7: 424-430.
24. Frieling H, Hillemacher T, Demling JH, et al. 2007. New options in the treatment of depression. Fortschr Neurol Psychiatr 75: 3-16.
25. Gao K, Calabrese JR. 2005. Newer treatment studies for bipolar depression. Bipolar Disord 5: 13-23.
26. Garcia-Mauriño S, Gonzalez-Haba MG, Calvo JR, et al. 1998. Involvement of molecular binding sites for melatonin in the regulation of, IL-2 and, IL-6 production by human blood mononuclear cells. J Neuroimmunol 92: 76-84.
27. Garcia-Mauriño S, Pozo D, Calvo JR, et al. 2000. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res 29: 129-137.
28. Garcia-Navarro A, Gonzalez-Puga C, Escames G, et al. 2007. Cellular mechanisms envolved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 43: 195-205.
29. Garcia-Pergañeda A, Pozo D, Guerrero JM, et al. 1997. Signal transduction for melatonin in human lymphocytes. Involvement of a pertussis toxin-sensitive G protein. J Immunol 159: 3774-3781.
30. Garzón C, Guerrero JM, Aramburu O, Guzmán T. 2009. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. Aging Clin Exp Res 21: 38-42.
31. Geddes JR, Burgess S, Hawton K, et al. 2004. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 161: 217-222.
32. Gitto E, Reiter RJ, Amodio A, et al. 2004a. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 36: 250-255.
33. Gitto E, Reiter RJ, Cordaro SP, et al. 2004b. Oxidative and inflamatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol 21: 209-216.
34. Gitto E, Reiter RJ, Sabatino G, et al. 2005. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J Pineal Res 39: 287-293.
35. Godbout JP, Glaser R. 2006. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. J Neuroimmune Pharmacol 1: 421-427.
36. Gonzalez-Maeso J, Ang RL, Yuen T, et al. 2008. Identification of a serotonin/glutamate receptor complex implicated in psicosis. Nature 452: 38-39.
37. Gould TD, O'Donnell KC, Dow ER, et al. 2008. Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swin test. Neuropharmacology 54: 577-587.
38. Guinjoan SM, Vigo DE, Castro MN, et al. 2008. Mood, Th1/Th2 cytokine profile, and autonomic activity in older adults with acute/ decompensated Herat failure: preliminary observations. World J Biol Psychiatry 20: 1-6.
39. Gutierrez-Cuesta J, Sureda FX, Romeu M, et al. 2007. Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8. J Pineal Res 42: 394-402.
40. Haney EM, Chan BK, Diem SJ, et al. 2007. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167: 1231-1232.
41. Hirsch-Rodriguez E, Imbesi M, Manev R, et al. 2006. The pattern of melatonin receptor expresion in the brain may influence antidepressant treatment. Med Hypotheses 69: 120-124.
42. Holsboer F, Ising M. 2008. Central CRH system in depression and anxiety. Evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583: 350-357.
43. Hung MW, Tipoe GL, Poon AM. 2008. Protective effect of melatonin against hippocampal injury of rats with intermittent hypoxia. J Pineal Res 44: 214-221.
44. Imbesi M, Uz T, Yildiz S, et al. 2006. Drug and region-specific effects of protracted antidepressant and cocaine treatment on the content of melatonin MT1 and MT2 receptor mRNA in the mouse brain. Int J Neuroprotec Neuroregen 2: 185-189.
45. Jakovijevic M, Bibic D, Crncevic Z, et al. 2008. Metabolic syndrome and depression in war veterans with post-traumatic stress disorder. Psychiatr Danub 20: 406-410.
46. Judd LL, Akiskal HS. 2003. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 73: 123-131.
47. Kabuto H, Yokoi I, Ogawa N. 1998. Melatonin inhibits iron-induced epileptic discharges in rats by suppressing peroxidation. Epilepsia 39: 237-243.
48. Kayumov L, Brown G, Jindal R, et al. 2001. A randomized double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep. Psychosom Med 63: 40-48.
49. Kim YK, Myint AM, Lee AM, et al. 2004. T-helper types 1,2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 129: 267-272.
50. Koliaskina GI, Sekirina TP, Androsova LV, et al. 2007. The influence of atypical neuroleptics on the immune system of patiems with schizophrenia. Vestn Ross Med Nauk 3: 14-19.
51. Kronfol Z, Nasrallah HA, Chapman S, et al. 1985. Depression, cortisol metabolism and lymphocytopenia. J Affect Disord 9: 169-173.
52. Lam RW, Bercowitz AL, Berga SL, et al. 1990. Melatonin suppression in bipolar and unipolar mood disorders. Psychiatry Res 33: 129-134.
53. Leonard BE, Song C. 1996. Stress and the immune system in the etiology of anxiety and depression. Pharmacol Biochem Behav 54: 299-303.
54. Leonard BE. 2006. HPA and immune axes in stress: involvement of the serotonergic system. Neuroimmunomodulation 13: 268-276.
55. Leonard BE. 2007. Psychopathology of depression. Drugs Today 43: 705-716.
56. Leonard BE, Myint A. 2006. Inflammation and depression: is there a causal connection with dementia? Neurotox Res 10: 149-160.
57. Leonard BE, Myint A. 2009. The psychoneuroimmunology of depression. Hum Psychopharmacol Clin Exp 24: 165-175.
58. Leonard BE, Song C. 2002. Changes in the immune system in rodent models of depression. Int J Neuropsychopharmacol 5: 345-356.
59. Lewy AJ. 1979. Plasma melatonin in manic-depressive illness. In Catecolamines: basic and clinical frontiers, Usdin E, Kopin IJ, Barchas J (eds). Pergamon: New York.
60. Lewys AJ, Wehr TA, Goodwin FK, et al. 1981. Manic-depressive patients may be supersensitive to light. Lancet 1: 383-384.
61. Lipartiti M, Franceschini D, Zanoni R, et al. 1996. Neuroprotective effects of melatonin. Adv Exp Med Biol 398: 315-321.
62. Liu C, Weaver DR, Jin X, et al. 1997. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadiam clock. Neuron 19: 91-102.
63. Macchi MM, Bruce JN. 2004. Human pineal physiology and funcional significance of melatonin. Front Neuroendocrinol 25: 177-195.
64. Maes M, Scharpe S, Bosmans E, et al. 1992. Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness. Prog Psychopharmacol Biol Psychiatry 16: 501-515.
65. Maes M, Bosmans E, Calabrese J, et al. 1995. Interleukin-2 and interleukin6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29: 141-152.
66. Maldonado MD, Siu AW, Sánchez-Hidalgo M. 2006. Melatonin and lipid uptake by murine fibroblasts: clinical implications. Neuroendocrinol Lett 27: 601-608.
67. Maldonado MD, Murillo-Cabezas F, Calvo JR, et al. 2007a. Melatonin as pharmacologic support in burn patients: a proposed solution to thermal injury-related lymphocytopenia and oxidative damage. Crit Care Med 35: 1177-1185.
68. Maldonado MD, Murillo-Cabezas F, Terron MP, et al. 2007b. The potencial of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res 42: 1-11.
69. Maslov B, Jakovljevic M, Crncevic Z, et al. 2008. Metabolic syndrome and schizophrenia from integrative medicine perspective. Psychiatr Danub 20: 384-389.
70. Matthias W, Wichmann MD, René MD, et al. 1996. Melatonin administration attenuates depressed immune functions after trauma-hemorrhage. J Surg Res 63: 256-262.
71. Mcintyre RS, Soczynska JK, Konarski JZ, et al. 2007. Should depressive syndromes be reclassified as "metabolic syndrome type II"? Ann Clin Psychiatry 19: 257-264.
72. Mcintyre RS, Muzina DJ, Kemp DE, et al. 2008. Bipolar disorder and suicide: research synthesis and clinical translation. Curr Psychiatry Rep 10: 66-72.
73. Molina-Carballo A, Muñoz-Hoyos A, Reiter JR, et al. 1997. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years experience. J Pineal Res 23: 97-105.
74. Morera AL, Abreu P. 2006. Seasonality of psychopathology and circannual melatonin rhythm. J Pineal Res 41: 279-283.
75. Moriya T, Horie N, Mitome M, et al. 2007. Melatonin influences the proliferative and differenciative activity of neural stem cells. J Pineal Res 42: 411-418.
76. Muller N, Schwarz MJ. 2007a. Inmunological aspects of depressive disoders. Nervenarzt 78: 1261-1273.
77. Muller N, Schwarz MJ. 2007b. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm Suppl 72: 269-280.
78. Myint AM, Leonard BE, Steinbusch HW, et al. 2005. Th1, Th2, and Th3 cytokine alterations in mayor depression. J Affect Disord 88: 167-173.
79. Na KS, Kim YK. 2007. Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 56: 55-63.
80. Newcomer JW. 2005. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 1: 1-93.
81. Nurnberger JI, Adkins S, Lahiri DK, et al. 2000. Melatonin supression by light in euthymic bipolar and unipolar. Arch Gen Psychiatry 57: 572-579.
82. Oken RJ. 1995. Towards a unifiying hypothesis of neurodegenerative diseases and a concomitant rational strategy for their prophylaxis and therapy. Med Hypotheses 45: 341-342.
83. Oken RJ. 2001. Obsessive-compulsive disorder: a neuronal membrane phospholipids hypothesis and concomitant therapeutic strategy. Med Hypotheses 56: 413-415.
84. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, et al. 2006. Melatonin: nature's most versatole biological signal? FEBS J 273: 2813-2838.
85. Paparrigopoulos T, Psarros C, Bergiannaki J, et al. 2001. Melatonin response to clonidine administration in depression: indication of presynaptic alpha2-adrenoceptor dysfunction. J Affect Disord 65: 307-313.
86. Paredes SD, Terrón MP, Valero V, et al. 2007. Orally administered melatonin improves nocturnal rest in young and old ringdoves. Basic Clin Pharmacol Toxicol 100: 258-268.
87. Perlis ML, Giles DE, Buysse DJ, et al. 1997. Self-reporter sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42: 209-212.
88. Peyrot F, Ducroig C. 2008. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 45: 235-246.
89. Pignone AM, Rosso DA, Fiori G, et al. 2006. Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarcoidosis. J Pineal Res 41: 95-100.
90. Potvin S, Stip E, Sepehry AA, et al. 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63: 801-808.
91. Radio NM, Doctor JS, Witt-Enderby PA. 2006. Melatonin enhaces alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grow in osteogenic medium via MT2 melatonin receptors and the MEK/ ERK (1/2) signalling cascade. J Pineal Res 40: 332-342.
92. Rapaport MH. 2007. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. J Clin Psychiatry 68: 42-46.
93. Reiter RJ. 2003. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 17: 273-285.
94. Reiter RJ, Tan DX, León J, et al. 2005a. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med 230: 104-117.
95. Reiter RJ, Tan DX, Maldonado MD. 2005b. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res 39: 215-216.
96. Reiter RJ, Tan DX, Sainz R, et al. 2002. Melatonin reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 54: 1299-1321.
97. Reiter RJ, Tan DX, Terron MP, et al. 2007. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochem Pol 54: 1-9.
98. Reiter RJ, Benitez-King G. 2009. Melatonin reduces neuronal loss and cytoskeletal deterioration: implications for psychiatry. Ment Health 32: 3-11.
99. Rihmer Z, Gonda X, Rhimer A. 2006. Creativity and mental illness. Psychiatr Hung 21: 288-294.
100. Robertson J, Peter E. 1997. Case study: the use of melatonin in a boy with refractory bipolar disorder. J Am Acad Child Adolesc Psychiatry 36: 822-825.
101. Roger MP. 2007. New antidepressant or more of the same? Neuropsychiatric disease and treatment. Editorial Foreword 3-5.
102. Sánchez-Hidalgo M, Lu Z, Tan DX. 2007. Melatonin inhibits fatty acidinduced triglyceride accumulation in ROS 17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol 292: 2208-2215.
103. Shamir E, Barak Y, Shalman I, et al. 2001. Melatonin treatment in tardive dyskinesia: adouble-blind, placebo-controlled, crossover study. Arch Gen Psychiatr 58: 1049-1052.
104. Shamir E, Rotenberg VS, Laudon M, et al. 2000. Firts-night effects of melatonin treatment in patients with chronic schizophrenia. J Clin Psychopharmacol 20: 691-694.
105. Shao L, Vawter MP. 2008. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry 64: 89-97.
106. Simko F, Paulis L. 2007. Melatonin as a potencial antihypertensive treatment. J Pineal Res 42: 319-322.
107. Simko F, Paulis L. 2008. Chronotherapy beyond blood pressure reduction? J Pineal Res 45: 227-228.
108. Song C, Horrobin DF, Leonard BE. 2006. The comparison of changes in behaviour, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1β in rats. Pharmacopsychiatry 39: 88-99.
109. Srinivasa V, Smits G, Kayumov L, et al. 2006. Melatonin in circadian rhythm sleep disorders. Neuroendocrine correlates of sleep-wakefulness. Springer: New York; 269-294.
110. Srinivasan V, Smits M, Spence W, et al. 2006. Melatonin in mood disorders. World J Biol Psychiatry 7: 138-151.
111. Srinivasan V, Spence DW, Trakh I, et al. 2008. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation. 15: 93-101.
112. Srinivasan V, Pandi-Perumal SR, Trakht I, et al. 2009. Pathophysiology of depresión: role of sleep and the melatonergic system. Psychiat Res 165: 201-214.
113. Suresh Kumar PN, Andrade C, Bhakta SG, et al. 2007. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry 68: 237-241.
114. Surman OS. 1993. Possible immunological effects of psychotropic medication. Psychosomatics 34: 139-143.
115. Szuster-Ciesielska A, Slotwinska M, Stachura A, et al. 2008. Accelerated apoptosis of blood leucocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32: 686-694.
116. Tan DX, Manchester LC, Reiter RJ, et al. 1999. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1472: 206-214.
117. Tan DX, Manchester LC, Terron MP, et al. 2007. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species. J Pineal Res 42: 28-42.
118. Taupin P. 2008. Adult neurogenesis, neuroinflammation and therapeutic potencial of adult neural ítem cells. Int J Med Sci 5: 127-132.
119. Teixeira PJ, Rocha FL. 2007. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 29: 330-336.
120. Tengattini S, Reiter RJ, Tan DX, et al. 2008. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 44: 16-25.
121. Tsai SY, Lee HC, Chen CC, et al. 2007. Cognitive impairment in later life in patients with early-onset bipolar disorders. Bipolar Disord 9: 868-875.
122. Vaccarino V, Johnson BD, Sheps DS, et al. 2007. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung and Blood Institute-sponsored WISE study. J Am Coll Cardiol 50: 2044-2050.
123. Van der Heijden DFFMMA, Tuinier S, Sjiben A, et al. 2005. Amino acids in schizophrenia: evidence for coger tryptophan availability during treatment with atypical antipsychotics? J Neural Transmi 112: 577-585.
124. Wadee AA, Kuschke RH, Wood LA, et al. 2002. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol Clin Exp 17: 175-179.
125. Walsh T, McClellan J, McCarthy SE, et al. 2008. Rare structural variants disrupt multiple genes in neurodevelopmental patways in schizophrenia. Science 320: 539-543.
126. Winkel R, Hert M, Eyck DV, et al. 2008. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 10: 342-348.
127. Wolden-Hanson T, Mitton DR, McCants RL, et al. 2000. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 141: 487-497.
128. Wyatt JK, Dijk DJ, Ritz-de Cecco A, et al. 2006. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadianphase dependent. Sleep 29: 609-618.
129. Yolken RH, Torrey EF. 1995. Viruses, schizophrenia, and bipolar disorders. Clin Microbiol Rev 8: 131-145.
130. Zee PC, Manthena P. 2007. The brain's master circadiam clok: implications and opportunities for therapy od sleep disorders. Sleep Med Rev 11: 59-70.
131. Zipris P, Melamed Y, Weizman A, et al. 2007. Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies. Isr J Psychiatry Relat Sci 44: 54-56.
132. Zorrilla ZM. 2003. Mechanism of action of lithium: intracellular signalling pathways. Vertex 14: 45-52.
133. Zupancic M, Guilleminault C. 2006. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 20: 981-992.